Update on gamma-hydroxybutyric acid;Actualización del ácido gamma-hidroxibutírico

Revista de Neurologia

Volumn 43, Issue 1, 2006, Pages 39-48

  Garcia F B ^a   Pedraza, C ^a   Navarro, José Francisco ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Aggression; Catalepsy; Drugs of abuse; Gamma hydroxybutyric acid (GHB); Neurotoxicity; Pharmacology; Sleep

Indexed keywords

4 HYDROXYBUTYRIC ACID; BENZODIAZEPINE; DOPAMINE RECEPTOR; GABAERGIC RECEPTOR AFFECTING AGENT; OXYBATE SODIUM; 4 HYDROXYBUTYRIC ACID RECEPTOR; 4-HYDROXYBUTYRIC ACID; 4-HYDROXYBUTYRIC ACID RECEPTOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CELL SURFACE RECEPTOR; HYDROXYBUTYRIC ACID; STREET DRUG;

AGGRESSION; ALCOHOL ABUSE; ALCOHOLISM; AMNESIA; BEHAVIOR; BRADYCARDIA; CATALEPSY; CENTRAL NERVOUS SYSTEM; CONFUSION; CONVULSION; DIARRHEA; DOPAMINERGIC SYSTEM; DREAMING; DROWSINESS; DRUG DEPENDENCE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; ELECTROPHYSIOLOGY; HALLUCINATION; HUMAN; HYPOMANIA; LOW DRUG DOSE; NARCOLEPSY; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; OPIATE ADDICTION; REM SLEEP DEPRIVATION; REVIEW; SEDATION; SOMNOLENCE; TREMOR; VERTIGO; VOMITING; WITHDRAWAL SYNDROME; ANIMAL; CHEMISTRY; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SECOND MESSENGER;

ANIMALS; BEHAVIOR; CENTRAL NERVOUS SYSTEM; HUMANS; HYDROXYBUTYRATES; NEUROTRANSMITTER AGENTS; RECEPTORS, CELL SURFACE; SECOND MESSENGER SYSTEMS; STREET DRUGS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33750092444     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4301.2005443     Document Type: Review

References (100)

1. Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol 1964; 3: 433-52.
2. Aizawa M, Ito, Y, Fukuda H. Pharmacological profiles of generalized absence in lethargic, stargazer and γ-hydroxybutyrate-treated model mice. Neurosci Res 1997; 29: 17-25.
3. Roth RH, Giarman NJ. Conversion in vivo of GABA to γ-hydroxybutyric acid in mammalian brain. Biochem Pharmacol 1969; 18: 247-50.
4. Ratomponirina C, Hodé Y, Hechler V, Maitre M. γ- hydroxybutyrate receptor binding in rat brain is inhibited by guanyl nucleotides and pertusis toxin. Neurosci Lett 1995; 189: 51-3.
5. Maitre M, Andrianmampandry C, Kemmel V, Schmdit C, Hodé Y, Hechler V, Gobaille S. γ-hydroxybutyric acid as signaling molecule in brain. Alcohol 2000; 20: 277-83.
6. Gallimberti L, Spella MR, Sloncini CA, Gessa GL. γ-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol 2000; 20: 257-62.
7. Scrima L, Hartman PF, Johnson FH, Thomas EE, Hiller FC. The effects of γ-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep 1990; 13: 479-90.
8. Vera F, Navarro JF. Efectos del ácido γ- hidroxibutírico (GHB) sobre el sueño y la activación. Vigilia/Sueño 1996; 7: 28-34.
9. Van Cauter E, Plat L, Scharf MB, Lepropult R, Céspedes S, L'Hermite M. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by γ-hydroxybutyrate in normal young men. J Clin Invest 1997; 100: 747-53.
10. Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend 2001; 63: 1-22.
11. Freese, TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat 2002; 23: 151-6.
12. Maitre M. The γ-hydroxybutyrate signaling system in brain: organization and functional implications. Prog Neurobiol 1997; 51: 337-61.
13. Cash CD. Gammahydroxybutyrate: an overview of pros and cons for it being a neurotransmitter and/or a useful therapeutic agent. Neurosci Biobehav Rev 1994; 18: 291-304.
14. Bernasconi R, Mathivet P, Bischoff S, Marescaux C. γ-hydroxybutyric acid: an endogenous neuromodulator with abuse potential? Trends Pharmacol Sci 1999; 20: 135-41.
15. De Fiebre CM, De Fiebre NEC, Coleman SL, Forster MJ. Comparison of the actions of γ-butirolactone and 1,4-butanediol in Swiss-Webster mice. Pharmacol Biochem Behav 2004; 77: 705-10.
16. Carter LP, Flores LR, Wu H, Chen W, Unzeiting AW, Coop A. The role of GABA-B receptors in the discriminative stimulus effects of γ- hydroxybutyrate in rats: time course and antagonism studies. J Pharmacol Exp Ther 2003; 305: 668-74.
17. Baker LE, Pynomen D, Poling A. Influence of reinforcer type and route of administration on γ-hydroxybutyrate discrimination in rats. Psychopharmacology (Berl) 2004; 174: 220-7.
18. 3H] GABA-B binding sites: relation to the development of experimental absence seizures. Brain Res 1994; 51: 335-61.
19. Carai MA, Colombo G, Reali R, Serra S, Mocci I, Castelli MP, et al. Central effects of 1,4-butanediol are mediated by GABA-B receptors via its conversion into γ-hydroxybutyric acid. Eur J Pharmacol 2002; 441: 157-63.
20. Carter LP, Chen W, Wu H, Mehta AK, Hernández J, Ticku MK, et al. Comparison of the behavioral effects of γ-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric (GHV). Drug Alcohol Depend 2005; 78: 91-9.
21. Winger G, Hursh SR, Casey KL, Woods JH. Relative reinforcing strenght of three N-methyl-D-aspartate antagonists with different onsets of action. J Pharmacol Exp Ther 2002; 301: 690-7.
22. Wong CGT, Gibson KM, Snead OC. From the street to the brain: neurobiology of the recreational drug γ-hydroxybutyric acid. Trends Pharmacol Sci 2003; 25: 29-34.
23. Vergoni AV, Ottani A, Botticeli AR, Zaffe D, Guano L, Loche A, et al. Neuroprotective effect of γ-hydroxybutyrate in the transient global cerebral ischemia in the rat. Eur J Pharmacol 2000; 397: 75-84.
24. Vayer P, Ehrhardt JD, Gobaille S, Mandel P, Maitre M. γ-hydroxybutyrate and turnover rates in discrete brain regions of the rat. Neurochem Int 1988; 12: 53-9.
25. Andriamampandry C, Taleb O, Viry S, Muller C, Humbert JP, Gobaille S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator γ-hydroxybutyrate (GHB). FASEB J 2003; 17: 1691-3.
26. Wu Y, Ali S, Ahmadian G, Liu CC, Wang YT, Gibson KM, et al. γ-hydroxybutyric acid (GHB) and GABA-BR binding sites are distinctive from one another: molecular evidence. Neuropharmacology 2004; 47: 1146-56.
27. Pedraza C, Navarro JF. Perfil farmacológico del ácido γ-hidroxibutírico. Psiquiatría Biológica 2001; 8: 25-32.
28. Hechler V, Gobaille S, Maitre M. Selective distribution of γ-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography. Brain Res 1992; 572: 345-8.
29. Waskielewic A, Bojarski J. γ-hydroxybutyric acid (GHB) and its chemical modifications: a review of the GHBergic system. Pol J Pharmacol 2004; 56: 43-9.
30. Castelli MP, Mocci I, Langlois X, Gommerendagger W, Luyten WH, Leysen JE, et al. Quantitative autoradiographic distribution of gamma-hydroxybutyric acid bindings sites in human and monkey brain. Brain Res 2000; 78: 91-9.
31. Vayer P, Maitre M. γ-hydroxybutyrate stimulation of the formation of cyclic GMP and inositol phosphates in rat hippocampal slices. J Neurochem 1989; 52: 1382-7.
32. Cash CD, Gobaille S, Kemmel V, Andriamanpandry C. γ-hydroxybutyrate receptor function studied by the modulation of nitric synthase activity in rat frontal cortex punches. Biochem Pharmacol 1999; 58: 1815-9.
33. Nelson T, Kaufman EE. Developmental time courses in the brain and kidney of two enzymes that oxidize γ-hydroxybutyrate. Dev Neurosci 1994; 16: 352-8.
34. Kaufman EE, Nelson T. An overview of γ-hydroxybutyrate catabolism: the role of the cytosolic NADP-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxoacid transhydrogenase in the initial, rate-limiting step in this pathway. Neurochem Res 1991; 16: 965-74.
35. Wong CGT, Bottiglieri T, Snead OC. GABA, γ-hydroxybutyric acid, and neurological disease. Ann Neurol 2003; 54 (Suppl 6): S3-12.
36. Gibson KM, Christensen E, Jacobs C, Fowler B, Clare MA, Hammersen G, et al The clinical phenotype of succinic semialdehyde deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Pediatrics 1997; 99: 567-74.
37. Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, et al. Dose-dependent absortion and elimination of γ-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993; 45: 353-6.
38. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: a review of the effects of γ-hydroxybutyric acid with recommendations for management. Ann Emerg Med 1998; 31: 729-36.
39. Dueñas A. Ácido γ-hidroxibutírico o 'éxtasis líquido', ¿la intoxicación que viene? Med Clin 1998; 111: 24-6.
40. Ferrara SD, Tedeschi L, Frison G, Orlando R, Mazzo M, Zordan R, et al. Effect of moderate or severe liver dysfunction on the pharmacokinetics of γ-hydroxybutyric acid. Eur J Clin Pharmacol 1996; 50: 305-10.
41. Ferrara SD, Zotti S, Tedeschi L. Pharmacokinetics of γ- hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 1992; 34: 231-5.
42. Scharf M, Lai A, Branigan B. Pharmacokinetics of γ-hydroxybutyrate (GHB) in narcoleptic patients. Sleep 1998; 21: 507-14.
43. Friedman J, Weslake R, Furman M. 'Grievous bodily harm': γ-hydroxybutyrate abuse leading to a Wernicke-Korsakoff syndrome. Am Acad Neurol 1996; 46: 469-71.
44. Royo-Isaach J, Magrané M, Vilà R, Capdevila ME. El 'éxtasis líquido' (GHB): ¿una droga de uso recreativo? Clínica biopsicosocial del consumidor y algunas propuestas terapéuticas. Atención Primaria 2004; 33: 516-20.
45. Borgen LA, Cook HN, Hornfeldt CS, Fuller DE. Sodium oxybate (GHB) for treatment of cataplexy. Pharmacotherapy 2002; 22: 798-9.
46. Beghe F, Carpanini MT. Safety and tolerability of γ-hydroxybutyric acid in the treatment of alcohol-dependent patients. Alcohol 2000; 20: 223-5.
47. McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of γ-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004; 75: 3-9.
48. Gallowey GP, Frederick-Osborne SL, Staggers Jr FE, Seymour R, Contini SE, Smith DE. Abuse and therapeutic potential of γ-hydroxybutyric acid. Alcohol 2000; 20: 263-9.
49. Colombo G, Agabio R, Balaklievskaia N, Díaz G, Lobina C, Reali R, et al. Oral self-administration of γ-hydroxybutyric acid in the rat. Eur J Pharmacol 1995; 285: 103-7.
50. Martellotta MC, Fattore L, Cossu G, Fratta W. Rewards properties of γ-hydroxybutyric acid: an evaluation through place preference paradigm. Psychopharmacology 1997; 132: 1-5.
51. Diana M, Mereu G, Mura, A, Fadda F, Passinoi N, Gessa GL. Low doses of γ-hydroxybutyric acid stimulate the firing rate of dopaminergic neurons in unanesthetized rats. Brain Res 1991; 566: 208-11.
52. Feigenbaum JJ, Howard SG. Naloxone reverses the inhibitory effect of γ-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study. Neurosci Lett 1997; 224: 71-4.
53. Maldonado C, Rodríguez-Arias M, Aguilar MA, Miñarro J. GHB ameliorates naloxone-induced conditioned place aversion and physical aspects of morphine withdrawal in mice. Psychopharmacology 2004; 177: 130-40.
54. Addolorato G, Caputo F, Capristo E, Bernardi IM, Stefanini GF, Gasbarrini G. A case of GHB withdrawal during alcohol addiction treatment utility of diazepam administration. Clin Neuropharmacol 1999; 22: 60-2.
55. Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R. γ-hydroxybutyric acid: Patterns of use, effects and withdrawal. Am J Addict 2001; 10: 232-41.
56. Price G. In-patient detoxification after GHB dependence. Br J Psychiatry 2000; 177: 81.
57. Craig K, Gómez HF, McManus JL, Bania TC. Severe γ-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000; 18: 65-70.
58. Colombo G, Agabio R, Lobina C, Reali R, Fadda F, Gessa GL. Cross-tolerance to ethanol and γ-hydroxybutyric acid. Eur J Pharmacol 1995; 273: 235-38.
59. Bania TC, Ashar T, Press G, Carey PM. γ-hydroxybutyric acid in the treatment of alcohol-dependent patients. Acad Emerg Med 2003; 10: 697-704.
60. Lamb RJ, Munn J, Duiker NJ, Coop A, Wu H, Koek W, et al. Interactions of γ-hydroxybutyric acid (GHB) binding sites in rat brain. Brain Res 2003; 979: 51-6.
61. 3H]NCS-382 in the rat brain. Drug Alcohol Depend 2004; 75: 323-5.
62. Berton F, Brancucci A, Beghè F, Cammaleri M, Demuro A, Francesconi W, et al. γ-hydroxybutyrate inhibits excitatory postsinaptic potentials in rat hippocampal slices. Eur J Pharmacol 1999; 380: 109-16.
63. Brancucci A, Berretta N, Mercuri NB, Francesconi W. GHB and ethanol depress spontaneous excitatory postsinaptic currents in dopaminergic neurons of the substantia nigra. Brain Res 2004; 997: 62-6.
64. Gobaille S, Schmidt C, Cupo A, Herbrecht F, Maitre M. Characterization of methionine enkephalin release in the rat striatum by in vivo dialysis: effects of γ-hydroxybutyrate on cellular and extracellular methionine enkephalin levels. Neuroscience 1994; 60: 637-48.
65. Monti JM, Altier H, D'Angelo L. The effects of the combined administration of hydroxybutyrate and diazepam on sleep parameters in the rat. J Neural Transm 1979; 45: 177-83.
66. Stock G, Heidt H, Buss J, Schlor KH. Sleep patterns in cat induced by γ-hydroxybutyric acid. Electroencephalogr Clin Neurophysiol 1977; 44: 523-7.
67. Godschalk M, Dzolijic MR, Bonta IL. Slow wave sleep and a state resembling absence epilepsy induced in the rat by γ-hydroxybutyrate. Eur J Pharmacol 1977; 44: 105-11.
68. Meerlo P, Westerveld P, Turek FW, Koehl M. Effects of γ-hydroxybutyrate (GHB) on vigilance states and EEG in mice. Sleep 2004; 27: 899-904.
69. Pedraza C, Navarro JF. Efectos clínicos y conductuales del ácido γ-hidroxibutírico. Psiquiatría Biológica 2001; 8: 146-60.
70. Thorpy M. Currents concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med 2001; 2: 5-17.
71. Williams SR, Turner JP, Crunelli V. γ-hydroxybutyrate promotes oscillatory activity of rat and cat thalamocortical neurons by a tonic GABA-B receptor-mediated hyperpolarization. Neuroscience 1995; 66: 133-41.
72. Depaulis A, Vergnes M, Marescaux C. Involvement of the nigra output pathways in the inhibitory control of the substantia nigra. Prog Neurobiol 1994; 42: 33-52.
73. Navarro JF, Martín-López M, Manzaneque JM, Pedraza C, Dávila G. Dose-dependent effect of γ-hydroxybutyrate (GHB) on catalepsy in male mice. Med Sci Res 1996; 24: 603-4.
74. Navarro JF, Pedraza C, Dávila G, Martín-López M. Effect of γ-hydroxybutyric acid (GHB) administration on catalepsy behaviour in female mice. Psicothema 2000; 12: 113-5.
75. Navarro JF, Pedraza C, Maldonado E, Cavas M. Absence of tolerance to cataleptic activity of γ-hydroxybutyrate after subchronic administration to male mice. Med Sci Res 1999; 27: 387-8.
76. Navarro JF, Pedraza C, Martín-López M, Manzaneque JM, Dávila G, Maldonado. Tiapride-induced catalepsy is potentiated by γ-hydroxybutyric acid administration. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 835-44.
77. Hechler V, Peter P, Gobaille S, Bourguignon JJ, Mark J, Maitre M. γ-hydroxybutyrate ligands posses antidopaminergic and neuroleptic-like activities. J Pharmacol Exp Ther 1993; 264: 1406-14.
78. Sevack RJ, France CP, Koek W. Neuroleptic-like effects of γ-hydroxybutyrate: interactions with haloperidol and dizocilpine. Eur J Pharmacol 2004; 483: 289-93.
79. Cavas M, Pedraza C, Navarro JF. Actualización del óxido nítrico. Psiquiatría Biológica 1999; 6: 175-87.
80. Navarro JF, Espert R. Sueño y demencia de Alzheimer. Vigilia/Sueño 1994; 2: 7-11.
81. Princhard PB. The effects of seizures on hormones. Epilepsia 1991; 32 (Suppl 6): S46-50.
82. Plangger C. Effect of gamma-hydroxybutyrate on intracranial pressure, mean systemic arterial pressure and cerebral perfusion pressure in experimentally induced brain edema of the rat. Zentralbl Neurochir 1990; 51: 24-33.
83. Navarro JF, Pedraza C. An ethopharmacological assessment of the effects of γ-hydroxybutyrate (GHB) on agonistic interactions in male mice. Med Sci Res 1996; 24: 817-9.
84. Martín-López M, Puigcerver A, Vera F, Navarro JF. Sulpiride shows an antiaggressive specific effect after acute treatment in male mice. Med Sci Res 1993; 21: 595-6.
85. Navarro JF, Velasco R, Manzaneque JM. Acute and subchronic effects of pimozide on isolation-induced aggression in male mice. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 131-42.
86. Navarro JF, González F, Pedraza C. Acute and subchronic effects of γ-hydroxybutyrate (GHB) on isolation-induced aggression in male mice. Eur Neuropsychopharmacol 2003; 13 (Suppl 4): S429.
87. Godbout R, Jelenic P, Labrie C, Schmitt M, Bourguignon JJ. Effect of gamma-hydroxybutyrate and its antagonist NCS-382 on spontaneous cell firing in the prefrontal cortex of the rat. Brain Res 1995; 673: 157-60.
88. García F. Neurotoxicidad del ácido gammahidroxibutí rico (GHB) en ratas: evidencia histológica y conductual [tesis doctoral]. Málaga: Universidad de Málaga; 2005.
89. Luna G, García F, Pedraza C, Dávila G, Martín M, Navarro JF. Effects of γ-hydroxybutyric acid (GHB) on memory tested in the hole-board in male mice. Eur Neuropsychopharmacol 2002; 11 (Suppl 3): S389.
90. Dávila G, García F, Pedraza C, Luna G, Martín M, Navarro JF. Effects of γ-hydroxybutyric acid (GHB) on memory tested in the hole-board in female mice. 4th Forum of European Neuroscience, Lisboa, julio 2004. URL: http://forum.fens.org/2004. Fecha última consulta: 20.11.2005.
91. García F, Pedraza C, Luna G, Navarro JF. Neurobehavioural evaluation of γ-hydroxybutyric acid (GHB), a new drug with abuse potential, in male rats. Eur Neuropsychopharmacol 2002; 11 (Suppl 3): S389.
92. García F, Pedraza C, Luna G, Navarro JF. Effects of subchronic administration of γ-hydroxybutyric acid (GHB) on memory tested in the hole-board in male rats. II Congreso Nacional de Psicobiología, septiembre 2002. Facultad de Psicología. Universidad de Almería.
93. Matsumura M, Kawashima R, Naito E, Satoh K, Takahashi T, Yanagisawa T, et al. Changes in rCBF during grasping in humans examined by PET. Neuroreport 1996; 7: 749-52.
94. Thierry AM, Gioanni Y, Dègenetais E, Glowinski J. Hippocampus-prefrontal cortex pathway: anatomical and electrophysiological characteristics. Hippocampus 2000; 10: 411-9.
95. García F, Pedraza C, Dávila G, Martín M, Arias JL, Navarro JF. Stereological quantification of adult mice hippocampus and prefrontal cortex after subchronic treatment with γ-hydroxybutyric acid (GHB). Trastornos Adictivos 2003; 5: 182.
96. Pedraza C, Navarro JF, Arias JL. Effects of L-NOARG, a nitric oxide synthase inhibitor, on Ag-NOR activity in striatum of mice. Psicothema 2002; 14: 605-7.
97. García F, Pedraza C, Navarro JF. Effects of γ- hydroxybutyrate (GHB) on Ag-NOR activity in hippocampus and prefrontal cortex of male rats. III Congreso Nacional de Psicobiología, Madrid, septiembre 2004.
98. Pedraza C, García F, Dávila G, Luna G, Navarro JF. Effects of γ-hydroxybutyric acid (GHB) on Ag-NOR activity in hippocampus and prefrontal cortex of male mice. 4th Forum of European Neuroscience, Lisboa, julio 2004. URL: http://forum.fens.org/2004. Fecha última consulta: 20.11.2005.
99. García-Moreno LM, Conejo NM, González-Pardo H, Gómez M, Martín FR, Alonso MJ, et al. Hippocampal AgNOR activity alter chronic consumption and alcohol deprivation in rats. Physiol Behav 2001; 72: 115-21.
100. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 1996; 93: 1956-61.